Northwestern University Feinberg School of Medicine

Rintaro Hashizume Lab

Publications

2017

Zhou J, Tien AC, Alberta JA, Ficarro SB, Griveau A, Sun Y, Deshpande JS, Card JD, Morgan-Smith M, Michowski W, Hashizume R, James CD, Ligon KL, Snider WD, Sicinski P, Marto JA, Rowitch DH, Stiles CD. A Sequentially Priming Phosphorylation Cascade Activates the Gliomagenic Transcription Factor Olig2. Cell Rep. 2017 Mar 28;18(13):3167-3177. doi: 10.1016/j.celrep.2017.03.003.

Wainwright DA, Horbinski C, Hashizume R, James CD. 2017. Therapeutic hypothesis testing with rodent brain tumor models. Neurotherapeutics. In Press.

Piunti A, Hashizume R, Morgan MA, Bartom ET, Horbinski CM, Marshall SA, Rendleman EJ, Ma Q, Takahashi YH, Woodfin AR, Misharin AV, Abshiru NA, Lulla RR, Saratsis AM2, Kelleher NL, James CD, Shilatifard A. Therapeutic targeting of polycomb and BET bromodomain proteins in diffuse intrinsic pontine gliomas. Nat Med. 2017 Feb 27. doi: 10.1038/nm.4296. [Epub ahead of print]

Maury E, Hashizume R. Epigenetic modification in chromatin machinery and its deregulation in pediatric brain tumors: Insight into epigenetic therapies. Epigenetics. 2017 Jan 6:1-17. doi: 10.1080/15592294.2016.1278095. [Epub ahead of print]

2016

Zhang J, Yao TW, Hashizume R, Hariono S, Barkovich KJ, Fan QW, Prados M, James CD, Weiss WA, Nicolaides T. Combined BRAFV600E and MEK blockade for BRAFV600E-mutant gliomas. Journal of Neuro-Oncology. 2016 Nov 15. [Epub ahead of print]. PMID: 27848137

Hashizume R, Zhang A, Mueller S, Prados MD, Lulla RR, Goldman S, Saratsis AM, Mazar AP, Stegh AH, Cheng SY, Horbinski C, Haas-Kogan DA, Sarkaria JN, Waldman T, James CD. Inhibition of DNA damage repair by the CDK4/6 inhibitor palbociclib delays irradiated intracranial atypical teratoid rhabdoid tumor and glioblastoma xenograft regrowth. Neuro Oncol. 2016 Jul 1. pii: now106. [Epub ahead of print]. PMID: 27370397

Olow A, Mueller S, Yang X, Hashizume R, Meyerowitz J, Weiss WA, Resnick AC, Waanders AJ, Stalpers LJ, Berger MS, Gupta N, James CD, Petritsch CK, Haas-Kogan DA. BRAF status in personalizing treatment approaches for pediatric gliomas. Clinical cancer research. 2016 May 23; [Epub ahead of print]. PMID: 27217440

Hashizume R, Gupta N. Patient-derived tumor models for diffuse intrinsic pontine gliomas. Current neuropharmacology. 2016 May 23; [Epub ahead of print]. PMID: 27212051

Lulla RR, Saratsis AM, Hashizume R. Mutations in chromatin machinery and pediatric high-grade glioma. Science Advances. 2016 Mar;2(3):e1501354 [Epub only]. PMID: 27034984

Clark AJ, Fakurnejad S, Ma Q, Hashizume R. Bioluminescence Imaging of an Immunocompetent Animal Model for Glioblastoma. J. Vis. Exp. 2016;(107), 53287, doi:10.3791/53287 (2016). PMID: 26863490.

Dasgupta T, Olow AK, Yang X, Hashizume R, Nicolaides TP, Tom M, Aoki Y, Berger MS, Weiss WA, Stalpers LJ, Prados M, James CD, Mueller S, Haas-Kogan DA. Erratum to: Survival advantage combining a BRAF inhibitor and radiation in BRAF V600E-mutant glioma. Journal of neuro-oncology. 2016 Feb;126(3):395. PMID: 26782702

Patil SA, Patil SA, Patil R, Hashizume R. Imidazoquinolines: Recent Developments in Anticancer Activity. Mini-Reviews in Medicinal Chemistry. 2016;16(4):309-22. PMID: 26675675

2015

Lerner RG, Grossauer S, Kadkhodaei B, Meyers I, Koeck K, Sidorov M, Hashizume R, Ozawa T, Berger MS, Nicolaides T, James CD, Petritsch C. Targeting a Plk1-Controlled Polarity Checkpoint in Therapy-Resistant Glioblastoma-Propagating Cells. Cancer Research. 2015 Dec 15;75(24):5355-66. PMID: 26573800. Epub 2015 Nov 16.

Dasgupta T, Olow AK, Yang X, Hashizume R, Tom M, Aoki Y, Berger MS, Weiss WA, Stalpers LJ, Prados M, David James C, Mueller S, Haas-Kogan DA. Survival advantage combining a BRAF inhibitor and radiation in BRAF-V600E-mutant glioma. J Neurooncol. 2015 Sep 18. [Epub ahed of print]. PMID: 26384810
 
Huang X, He Y, Dubuc AM, Hashizume R, Zhang W, Reimand J, Yang H, Wang TA, Stehbens SJ, Younger S, Barshow S, Zhu S, Cooper MK, Peacock J, Ramaswamy V, Garzia L, Wu X, Remke M, Forester CM, Kim CC, Weiss WA, James CD, Shuman MA, Bader GD, Mueller S, Taylor MD, Jan YN, Jan LY. EAG2 potassium channel with evolutionarily function as a brain tumor target. Nat Neurosci. 2015 Sep;18(9):1236-46. PMID: 26258683
   
Morales La Madrid A, Hashizume R, Kieran MW. Future Clinical Trials in DIPG: Bringing Epigenetics to the Clinic. Front Oncol. 2015 Jul 1;5:148. Review. PMID: 26191506

2014

Clark AJ, Safaee M, Oh T, Ivan ME, Parimi V, Hashizume R, Ozawa T, James CD, Bloch O, Parsa AT. J Transl Med. 2014 Dec 3;12:345. PMID: 25464980
 
Hashizume R*, Andor N, Ihara Y, Lerner R, Gan H, Chen X, Fang D, Huang X, Tom MW, Ngo V, Solomon D, Mueller S, Paris P, Zhang Z, Petritsch C, Gupta N, Waldman T, James CD. Pharmacologic inhibition of histone demethylation as a therapy for pediatric brainstem glioma. Nat Med. 2014 Dec;20(12):1394-6. PMID: 25401693. *co- corresponding author.
 
Mueller S, Hashizume R, Yang X, Kolkowitz I, Olow AK, Phillips J, Smirnov J, Tom MW, Prados MD, James CD, Berger MS, Gupta N, and Haas-Kogan DA (2013). Targeting Wee1 for the treatment of pediatric high-grade gliomas. Neuro Oncol, 2014 Mar;16(3):352-60. PMID: 24305702

2013

Weng KC, Hashizume R, Noble CO, Serwer LP, Drummond DC, Kirpotin DB, Kuwabara AM, Chao LX, Chen FF, James CD, and Park JW. Convection-enhanced delivery of targeted quantum dot-immunoliposome hybrid nanoparticles to intracranial brain tumor models. Nanomedicine (Lond). 2013 Dec;8(12): 1913-25. PMID: 23631502
 
Chan KM, Fang D, Gan H, Hashizume R, Yu C, Schroeder M, Gupta N, Mueller S, James CD, Jenkins R, Sarkaria J, Zhang Z. The histone H3.3K27M mutation in pediatric glioma reprograms H3K27 methylation and gene expression. Genes Dev. 2013 May;27(9):985- 90. PMID: 23603901
 
Silber J, Hashizume R, Felix T, Hariono S, Yu M, Berger MS, Huse JT, VandenBerg SR, James CD, Hodgson JG, Gupta N. Expression of miR-124 inhibits growth of medulloblastoma cells. Neuro Oncol. 2013 Jan;15(1):83-90. PMID: 23172372

2012

Hashizume R, Smirnov I, Liu S, Phillips JJ, Hyer J, McKnight TR, Wendland M, Prados M, Banerjee A, Nicolaides T, Mueller S, James CD, Gupta N. Characterization of a diffuse intrinsic pontine glioma cell line: implications for future investigations and treatment. J Neurooncol. 2012 Dec;110(3):305-13. PMID: 22983601
 
Huang X, Dubuc AM, Hashizume R, Berg J, He Y, Wang J, Chiang C, Cooper MK,  Northcott PA, Taylor MD, Barnes MJ, Tihan T, Chen J, Hackett CS, Weiss WA, James CD, Rowitch DH, Shuman MA, Jan YN, Jan LY. Voltage-gated potassium channel EAG2 controls mitotic entry and tumor growth in medulloblastoma via regulating cell volume dynamics. Genes Dev. 2012 Aug;26(16):1780-96. PMID: 22855790
 
Huillard E, Hashizume, R*, Phillip, JJ, Griveau, A, Aoki, Y, Nicolides, T, Perry, A,  Waldman, T, McMahon, M, Weiss, WA, James, CD, Rowitch, D. Cooperative interactions of BRAFV600E and CDKN2A deficiency in pediatric high-grade glioma as a basis for rational therapy. Proc Natil Acad Sci USA. 2012 May;109(22):8710-5. *co- first author.
 
Aoki Y, Hashizume R, Ozawa T, Banerjee A, Prados MD, James CD, Gupta N. An experimental xenograft mouse model of diffuse pontine glioma designed for therapeutic testing. J Neurooncol. 2012 May;108(1):29-35.

2011

Nicolaides TP, Li H, Solomon DA, Hariono S, Hashizume R,  Barkovich  K,  Baker  SJ,  Paugh BS, Jones C, Forshew  T, Hindley  GF, Hodgson  JG, Kim JS, Rowitch  DH, Weiss  WA, Waldman TA, James CD. Targeted Therapy for BRAFV600E Malignant Astrocytoma. Clin Cancer Res. 2011 Dec; 17: 7595-604.
 
Hashizume R. New Therapeutic Strategies for the Treatment of Brain Tumor, in Brain tumors - Current and Emerging Therapeutic Strategies (Ana Lucia Abujamra, ed.), pp. 191-208, InTech, Croatia, 2011.

2010

Serwer L, Hashizume R, Ozawa T, James CD. Systemic and local drug delivery for  treating diseases of the central nervous system in rodent models. J Vid Exp. 2010 Aug; 42: http://www.jove.com/index/details.stp?id=1992.
 
Zhu X, Bidlingmair S, Hashizume R, James CD, Berger MS, Liu B. Identification of internalizing human single chain antibodies targeting brain tumor sphere cells. Mol Cancer Ther. 2010 Jul; 9 (7): 2131-41.
 
Hashizume R and Gupta N. Intranasal delivery of a telomerase inhibitor for the treatment of brain tumors. Curr Opin Mol Ther. 2010 Ap r; 12 (2):168-175.
 
Hashizume R, Gupta N, Berger MS, Banerjee A, Prados MD, Ayers-Ringler J, James CD and VandenBerg SR. Morphologic and molecular characterization of ATRT xenografts adapted for orthotopic therapeutic testing. Neuro-Oncol. 2010 Ap r; 12 (4):366-376.
 
Hashizume R, Ozawa T, Dinca EB, Banerjee A, Prados MD, James CD,  Gupta  N.  A human brainstem tumor xenograft enabled for bioluminescence imaging. J. Neurooncol. 2010 Jan; 96(2):151-159.

2008

Hashizume, R, Ozawa, T., Gryaznov, SM, Bollen, AW., Lamborn, KR, Frey II, WH. and Deen, DF. New therapeutic approach for brain tumor: Intranasal delivery of telomerase inhibitor GRN163 into intracerebral glioblastoma xenografts. Neuro- Oncol. 2008 Ap r; 10 (2): 112-120.
 
Hashizume,  R  and  Frey  II,  WH.  Intranasal  Delivery-A  New  Therapeutic  Approach  for Brain Tumors. US Neurology. 2008 Nov;4 (2): 43-44.

2002

Fukuda M, Miyamoto K, Hashizume R, Okamoto J, Kawamoto H, Yabuki Y, Ogata H, Ohta
T. Breast Cancer. Gan To Kagaku Ryoho. 2002 Nov;29(11):1900-6. Japanese.

2001

Hashizume R, Fukuda M, Maeda I, Nishikawa H, Oyake D, Yabuki Y, Ogata H, Ohta T. The RING heterodimer BRCA1-BARD1 is a ubiquitin ligase inactivated by a breast cancer-derived mutation. J. Biol Chem. 2001 May; 276 (18): 14537- 14540.
 
Ohta,  T,  Hashizume,   R,  Fukuda,  M.  Novel  function  of  BRCA-1,   as  BRCA1-BARD1 ubiquitin ligase, Cell Technology. 2001;20(6): 854-856.  Japanese

2000

Grothey  A, Hashizume  R, Ji H, Tubb  BE, Patric  CW, Yu D, Mooney  EE,  McCrea  PD. C-erb-2/HER-2   upregulates   fascin,   an   actin-bundling   protein   associated   with   cell motility, in human cancer cell lines. Oncogene. 2000  Oct; 19 (42): 4864-4875.
 
Grothey A, Hashizume R, Sahin AA, McCrea, PD. Fascin, an actin-bundling protein associated with cell motility, is upregulated in hormone receptor negative breast cancer. Br. J. Cancer. 2000 Oct;83 (7): 870-873.

1997

Yamamura T, Matsuzaki H, Hashizume R, Arifuku T, Adachi Y, Nagaoka S, Kimura M, Akaishi O, Tsukikawa S. Continuous hepatic arterial infusion of fluorouracil with leucovorin for liver metastases from colorectal cancer. Gan To Kagaku Ryoho. 1997 Sep;24(12):1691-4. Japanese
 
Ohta T, Fukuda M, Arima K, Kawamoto H, Hashizume R, Arimura T, Yamaguchi S. Analysis of Cdc2 and Cyclin D1 Expression in Breast Cancer by Immunoblotting. Breast Cancer. 1997 Mar 25;4(1):17-24.

1996

Hashizume R, Koizumi H, Ihara A, Ohta T, Uchikoshi T. Expression of beta-catenin in normal breast tissue and breast carcinoma: a comparative study with epitherial cadherin and alpha-catenin. Histopathology. 1996 Aug;29(2):139-46.
 
Ihara A, Koizumi H, Hashizume R, Uchikoshi T. Expression of epithelial cadherin and alpha-and beta-catenins in nontumoral lives and hepatocellular carcinomas. Hepatology. 1996 Jun;23(6):1441-7.

1995

Hashizume   R,  Koizume   H,   Uchikoshi   T.  Expression   of  epithelial   cadherin   and  b- catenin in breast carcinomas.  St. Marianna Med. J. 1995;23: 883-890.
 
Hashizume  R,  Koizume  H,  Takakuwa  T,  Uchikoshi,  T.  Expression  of  E-cadherin  and cathepsin D in breast cancer. Jpn. J. Breast Cancer. 1995;10:383-388. Japanese
 
Yamamura, T, Oikaawa, H, Hanai, A, Matsuzaki, H, Akaishi, O,  Seo,  K,  Kikuchi,  K,  Ozasa, T, Tsukikawa, S, Yamaguchi, S, Hashizume, R, Ihara, A and Takakuwa, T. Pharmacokinetic study in biochemical modulation therapy of UFT with Leucovorins tablet. 1995;Jpn. J. Cancer Chemother. 22: 245-251.
 
Miyake, H, Maeyama, S, Hashizume, R, Ihara, A, Okamoto, N, Aida, Y, Takakuwa, T and Uchikoshi, T. Fibrotic changes correlation between-liver and other organs-Histopathological studies in autopsy cases of alcoholic patients. Alchole and Medical Bio. 1993;13: 157-162.